24 januari 2011: Bron: Medscape

Sorafenib blijkt nog een effectief medicijn te kunnen zijn voor patiënten met GIST - Gastro Intertestinal Stroma Tumor, waarbij zij  resistent zijn geworden voor Gleevec en Sutent. Dit blijkt uit een kleinschalige maar wel gerandomiseerde studie. Hier een citaat uit een artikel uit Medscape over deze studie. Het hele artikel is te lezen als u hier klikt.

Activity Seen in Resistant Patients

The study was designed to evaluate the effectiveness of sorafenib in patients with unresectable KIT-expressing GIST who had disease progression despite treatment with imatinib. The study was amended in 2007 — after approval by the US Food and Drug Administration of sunitinib for patients resistant to imatinib — to require progression after both imatinib and sunitinib.

The participants were 6 patients who were resistant to imatinib only (from the initial cohort) and 32 who demonstrated resistance to both agents. The primary end point was objective response rate; secondary end points included toxicity, progression-free survival, and overall survival.

Patients received sorafenib 400 mg orally twice daily for a 28-day cycle, and computed tomography scans were performed every 2 cycles. The median follow-up for survivors was 31 months.

The study found 1 confirmed partial response in the group resistant to imatinib only (17%) and 4 in the group resistant to both imatinib and sunitinib (13%).

Median progression-free survival was 3.4 months in the group resistant to imatinib only and 5.2 months in the group resistant to both agents. Median overall survival was 13.6 months and 10.5 months, respectively.

Dose reductions were required in 63% of patients, primarily for hand-foot syndrome (45%) and hypertension (21%), which were the most common grade 3 toxicities, explained Dr. Campbell.

"These data demonstrate that sorafenib has definite activity in imatinib- and sunitinib-resistant GIST," he concluded. "Prolonged disease control is possible in these refractory patients, even those with primary sunitinib resistance. [National Comprehensive Cancer Network] guidelines now recommend sorafenib as an option for patients with imatinib- and sunitinib-resistant GIST."

Plaats een reactie ...

Reageer op "Sorafenib blijkt soms nog effectief medicijn na optreden resistentie voor Gleevec en Sutent bij patienten met GIST"

Gerelateerde artikelen

Gerelateerde artikelen

Langer gebruik van imatinib >> GIST - Gastro Intertestinal >> Sorafenib blijkt soms nog >> Gleevec - Imatinib is het >> Sugen - Sutent geeft voor >> Een laparoscopische verwijdering >> GIST - Gastro Intertestinal >>